Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033864 | 0.81 | TGFBR1 (0.82) | TGFBR1MAPK14MAPTALDH1A1LMNA | |
| SCHEMBL4031845 | 0.80 | TGFBR1 (0.68) | TGFBR1MAPK14DYRK1A | |
| SCHEMBL4033122 | 0.77 | TGFBR1 (0.58) | TGFBR1MAPK14MAPTALDH1A1LMNA | |
| SCHEMBL5695774 | 0.77 | TGFBR1 (0.55) | TGFBR1MAPK14DYRK1AMAPTALDH1A1 | |
| SCHEMBL25366177 | 0.76 | DYRK1A (0.43) | TGFBR1MAPK14DYRK1AMAPTALDH1A1 | |
| SCHEMBL30520086 | 0.76 | DYRK1A (0.43) | TGFBR1MAPK14DYRK1AMAPTALDH1A1 | |
| SCHEMBL4032677 | 0.75 | TGFBR1 (0.54) | TGFBR1MAPK14MAPTALDH1A1LMNA | |
| SCHEMBL5656833 | 0.75 | TGFBR1 (0.53) | TGFBR1MAPK14MAPTALDH1A1LMNA | |
| SCHEMBL4035145 | 0.74 | TGFBR1 (1.00) | TGFBR1MAPK14MTOR | |
| SCHEMBL4032214 | 0.74 | TGFBR1 (1.00) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527720-A | — | — | 2006-12-07 | — | — | JP | claimed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | claimed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMAD3, ALK, SMAD2 | TGFBR1 4/4885MAPK14 386/4885DYRK1A 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.